Arcus Biosciences, Inc. (NYSE:RCUS) Receives $24.13 Average PT from Analysts

Shares of Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) have earned an average rating of "Moderate Buy" from the nine analysts that are presently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $21.29.

Several research analysts have recently weighed in on the company. The Goldman Sachs Group reduced their price objective on Arcus Biosciences from $15.00 to $13.00 and set a "neutral" rating for the company in a research report on Thursday, May 8th. HC Wainwright upgraded Arcus Biosciences from a "neutral" rating to a "buy" rating and upped their target price for the stock from $18.00 to $24.00 in a report on Wednesday, February 26th. Wedbush reiterated an "outperform" rating and set a $33.00 target price on shares of Arcus Biosciences in a report on Wednesday, May 7th. Barclays dropped their target price on Arcus Biosciences from $29.00 to $14.00 and set an "overweight" rating on the stock in a report on Wednesday, April 23rd. Finally, Wells Fargo & Company dropped their target price on Arcus Biosciences from $29.00 to $26.00 and set an "overweight" rating on the stock in a report on Wednesday, May 7th.

Arcus Biosciences Stock Down 1.1%

Shares of RCUS stock traded down $0.10 on Monday, hitting $8.53. 637,295 shares of the stock were exchanged, compared to its average volume of 868,763. The company has a current ratio of 5.37, a quick ratio of 5.37 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $902.71 million, a P/E ratio of -2.03 and a beta of 0.83. The business has a 50-day moving average of $8.80 and a 200 day moving average of $10.78. Arcus Biosciences has a fifty-two week low of $6.50 and a fifty-two week high of $18.98.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($1.14) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.12). The firm had revenue of $28.00 million for the quarter, compared to analyst estimates of $38.61 million. Arcus Biosciences had a negative return on equity of 70.58% and a negative net margin of 258.94%. The firm's quarterly revenue was down 80.7% on a year-over-year basis. During the same period in the prior year, the company earned ($0.05) earnings per share. Equities analysts anticipate that Arcus Biosciences will post -3.15 EPS for the current year.

Institutional Trading of Arcus Biosciences

Several institutional investors and hedge funds have recently bought and sold shares of RCUS. Strs Ohio bought a new stake in Arcus Biosciences in the first quarter valued at approximately $67,000. E Fund Management Co. Ltd. bought a new stake in Arcus Biosciences in the first quarter valued at approximately $82,000. Lazard Asset Management LLC raised its stake in Arcus Biosciences by 3,321.3% in the fourth quarter. Lazard Asset Management LLC now owns 6,261 shares of the company's stock valued at $93,000 after buying an additional 6,078 shares during the period. Knott David M Jr bought a new stake in Arcus Biosciences in the first quarter valued at approximately $94,000. Finally, US Bancorp DE raised its stake in Arcus Biosciences by 2,432.0% in the fourth quarter. US Bancorp DE now owns 6,887 shares of the company's stock valued at $103,000 after buying an additional 6,615 shares during the period. Institutional investors own 92.89% of the company's stock.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.